Novo Nordisk Second Quarter 2025 Earnings: EPS Misses Expectations

Explore Novo Nordisk's Fair Values from the Community and select yours

Novo Nordisk (CPH:NOVO B) Second Quarter 2025 Results

Key Financial Results

• Revenue: kr.76.9b (up 13% from 2Q 2024).
• Net income: kr.26.5b (up 32% from 2Q 2024).
• Profit margin: 35% (up from 30% in 2Q 2024). The increase in margin was driven by higher revenue.
• EPS: kr.5.97 (up from kr.4.50 in 2Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Novo Nordisk EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.9%.

Looking ahead, revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Denmark.

The company's shares are down 11% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Novo Nordisk (at least 2 which are potentially serious), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.